German multicenter phase II trial to study effectivity and feasibility of alemtuzumab (MabCampath) in T-ALL [T-cell acute lymphoblastic leukaemia] and T-lymphoblastic lymphomas with minimal residual disease, in refractory relapse or in primary failure

Trial Profile

German multicenter phase II trial to study effectivity and feasibility of alemtuzumab (MabCampath) in T-ALL [T-cell acute lymphoblastic leukaemia] and T-lymphoblastic lymphomas with minimal residual disease, in refractory relapse or in primary failure

Completed
Phase of Trial: Phase II

Latest Information Update: 01 Aug 2016

At a glance

  • Drugs Alemtuzumab (Primary)
  • Indications Acute lymphoblastic leukaemia; Non-Hodgkin's lymphoma
  • Focus Therapeutic Use
  • Most Recent Events

    • 29 May 2008 The expected completion date for this trial is now 1 Dec 2007, according to ClinicalTrials.gov.
    • 29 May 2008 Status changed from recruitiing to completed, reported by ClinicalTrials.gov.
    • 22 Oct 2005 New trial record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top